DVADaVita

Health care · Health Services · NYSE

Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. 10-K, Item 1

Headquarters: Denver, CO
CEO: Javier Rodriguez
Next results: around Feb 1, 2027

Compare with peers → Embed

Key numbers

Latest fiscal year, with ten years behind each

RevenueFY2016–25 $13.6B+6.5% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $746.8M−20.2% FY2024: $936.3M 10-K FY2025 · XBRL Free cash flowFY2016–25 $1.3B−10.6% FY2024: $1.5B 10-K FY2025 · XBRL Operating marginFY2016–25 15.0%−1.3 pts 19.0% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 11, 2026 against Feb 13, 2025

Area	What changed	Source
Risk factors	29 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Inventory growing faster than revenue	Inventory +19.4% vs revenue +6.5% (+12.9 pts)	10-K · XBRL
Accounting checks	10 other checks clear, 1 worth a look	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	2 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 11, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-13. Quoted as filed.

Risks Related to Competition, Business Strategy Growth, Information Systems and New Technologies
10-K, Item 1A

All 29 new paragraphs →

Accounting checks

latest 10-K

10 of 11 clear 1 worth a look. Checks, not verdicts.

!
Inventory growing faster than revenueInventory +19.4% vs revenue +6.5% (+12.9 pts)
✓
Receivables +12.5% vs revenue +6.5% (+6.0 pts)
✓
Cash from operations $1.9B vs net income $746.8M (FY ending 2025-12-31)
✓
Same auditor in both 10-Ks: KPMG LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
The same matters as last year: U.S. dialysis patient service revenue recognition; F-2; Evaluation of legal proceedings and regulatory matters
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Oct 29, 20268-K Quarterly results 8-K item 2.02
Oct 29, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026

About DaVita

10-K, Feb 11, 2026

Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at http://www.davita.com, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC).

Headquarters: Denver, CO
Country: United States
Reports in: USD
Listed on: NYSE
Fiscal year ends: December 31
Last results: Oct 29, 2026
Incorporated in: DE

Permanent link, kept if the ticker changes: /c/sec:0000927066 (SEC's CIK).

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on DVA in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DVA/export.csv") into a cell.